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ADOPTIVE INFUSION OF DONOR NK CELLS REDUCES GVHD IN RECIPI-
ENTS OF T-CELL DEPLETED AND T-CELL REPLETE ALLOGENEIC MHC-
MATCHED HEMATOPOIETIC STEM CELL TRANSPLANTATION
Lundqvist, A., Childs, R. NHLBI, NIH, Bethesda, MD.
Retrospective data suggest that alloreactive NK cell-mediated re-
duction in GVHD and disease relapse may be limited to patients
with AML undergoing T-cell depleted KIR ligand-mismatched al-
logeneic hematopoietic cell transplantation (HCT). Whether NK
cells can mediate similar beneficial effects following MHC-
matched, T-cell replete allogeneic HCT is currently unknown.
We investigated if an infusion of purified donor NK cells would re-
duce GVHD and simultaneously mediate anti-tumor effects in
a murine solid tumor model of MHC-matched allogeneic HCT.
Ten days following intravenous injection of 105 RENCA tumor
cells, BALB/c recipient mice were irradiated (950 cGy) and trans-
planted with 8  106 bone marrow cells from MHC-matched
B10.d2 donors. Recipients of a T-cell replete HCT additionally re-
ceived 15 106 splenocytes fromMHC-matched B10.d2 donors on
day 0 whereas recipients of a T-cell depletedHCT received no sple-
nocytes on day 0 with or without a delayed infusion of donor lym-
phocytes (15  106 splenocytes) on day 14. All mice in groups
receiving splenocytes (day 0 or day 14) developed GVHD (weight
loss, alopecia and hunched posture) by day130 and died before day
160. In contrast, 60% of mice receiving splenocytes and purified
donor NK cells (0.5–5  106) on day 0 or day 14 remained free
of skin GVHD and had significantly lower GVHD scores (see Ta-
ble). Moreover, 40% of transplant recipients receiving splenocytes
and NK cells on either day 0 or day 14 survived $60 days post
transplant. To further characterize the NK cell subset responsible
for prolonging GVHD-free survival, donor NK cells were sorted
into BALB/c non-alloreactive Ly49 ligand-matched (Ly49G2)
and BALB/c alloreactive Ly49 ligand-mismatched (Ly49C) NK
cells. Recipients of Ly49C1 NK cells (given day 15) had signifi-
cantly less GVHD and prolonged survival (p\ 0.01) compared to
HCT recipients receiving Ly49G21 NK cells. No difference inorts of
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0.2
ups #3
.GVHD-free survival was observed between transplant recipients
of Ly49G21NK cells and controls not receiving NK cells. Pulmo-
nary tumor burdenwas significantly (p\0.01) lower in recipients of
Ly49C1 or Ly49G21 NK cells compared to mice not receiving
NK cells. These data provide in vivo evidence that a single infusion
of alloreactive donor NK cells can prolong survival by both reduc-
ing GVHD and mediating anti-tumor effects following MHC-
matched T-cell replete allogeneic HCT.STEM CELL BIOLOGY72
RECIPIENT BASED STRATEGIES FOR IMPROVED TRANSPLANT EFFI-
CIENCY: CD26 INHIBITOR TREATED AND CD26-/- RECIPIENT MICE EX-
HIBIT INCREASED SHORT-TERM HOMING AND LONG-TERM
ENGRAFTMENT OF HEMATOPOIETIC STEM AND PROGENITOR CELLS
Paganessi, L.A., Gregory, S.A., Fung, H.C., Christopherson, K.W. Rush
University Medical Center, Chicago, IL.
Introduction: Through the use of CD26 inhibitors and CD26
deficient mice (CD26-/-), we have previously generated data sug-
gesting that suppression of CD26/DPPIV activity on the transplant
donor cell population could potentially be utilized clinically as
a method of increasing transplant efficiency. However, the clinical
importance of the transplant recipient should not to be overlooked.
We therefore investigated whether inhibition or loss of CD26 activ-
ity in the recipient would have an effect on hematopoietic stem cell
transplantation utilizing an in vivo congenic mouse model of trans-
plantation. Methods: The short-term homing and long-term en-
graftment of BoyJ donor cells (expressing CD45.11) into lethally
irradiated control C57BL/6, CD26 inhibitor (Diprotin A) treated
C57BL/6, or CD26-/- mice (expressing CD45.21) was monitored
by flow cytometric analysis of the bone marrow and peripheral
blood at 24 hours and 6 months post-transplant. Results:
Twenty-four hours post-transplant of 20  106 BoyJ mononuclear
cells, we observed 8.85 6 0.58%, 10.69 6 1.01%, and 12.45 6
1.33% donor derived Sca-11lin- cells in the bone marrow of recip-
ient mice for control, Diprotin A treated, and CD26-/- recipient
mice respectively. As compared to control mice, this represents
a 20.8% increase (p 5 0.01) with CD26 inhibitor treatment and
a 40.7% increase (p# 0.05) resulting from the use of a CD26-/- re-
cipient in short-term homing (N 5 5 mice per group). Six months
post-transplant of 1  105 BoyJ mononuclear cells, we observed
39.906 4.38%, 70.226 3.72%, and 92.51 6 1.04% donor contri-
bution to hematopoiesis in the peripheral blood of control, Dipro-
tin A treated, and CD26-/- recipient mice respectively. This
represents a 76.0% increase (p # 0.01) with CD26 inhibitor treat-
ment and a 131.9% increase (p# 0.01) as a result of the CD26-/- re-
cipient in long-term engraftment as compared to control recipient
mice (N5 14 mice per group).Conclusions:These results provide
pre-clinical evidence of the importance of CD26 expression within
the transplant recipient with regard to regulating hematopoietic
stem cell homing and engraftment. Our results also support the po-
tential use of CD26 inhibitors to treat transplant patients during he-
matopoietic stem cell transplantation as a method of improving
transplant efficiency.
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HUMAN HEMATOPOIETIC PROGENITORS WITH SLOW DIVISIONAL KI-
NETICS RECONSTITUTE T CELLS IN THYMUS, B CELLS IN LYMPH NODES
AND MYELOID CELLS IN MARROW OF NOD/SCID MOUSE MODEL AND
REPRESENT THE MOST PRIMITIVE FRACTION
Schubert, M.1, Zoeller, M.2, Ho, A.D.1. 1University of Heidelberg, Hei-
delberg, Germany; 2German Cancer Research Center, Heidelberg, Ger-
many.
We have demonstrated that CD341 cells with slow division ki-
netics are associated with self renewal and increased frequency of
LTC-IC and myeloid-lymphoid initiating cells (ML-IC) in vitro.
The present study showed that only the slow dividing fraction
(SDF) of human CD341 cells, but not the fast dividing fraction
(FDF), is able to engraft the thymus and lymph nodes of NOD/
SCID mice.
30 Oral PresentationsHuman CD341 cells were isolated from umbilical cord blood,
stained with the membrane fluorescence marker PKH26, cultivated
in cytokine richmedia for five days and then sorted for their PKH26
fluorescence (dim versus bright, i.e. FDF versus SDF). Sorted cells
were injected into the tail vein of sublethally irradiatedNOD/SCID
mice (2  105 cells/animal). The animals were sacrificed at defined
time points from week 2 to 18 after transplantation. Flow cytomet-
ric analysis of the samples collected from the marrow, spleen, thy-
mus, and lymph nodes of the NOD/SCID mice indicated that
both SDF and FDFwere able to engraft the bone marrow of the an-
imals, i.e. erythroid and myeloid progenitor cells were recovered
from the bone marrow of SDF and FDF repopulated mice. The
most remarkable finding was that only cells of SDF origin were
found in the lymph nodes and thymus where, at week 15 they differ-
entiated into T cells. CD41CD81 double positive T progenitor
cells were recovered in the thymus and CD41 as well as CD81
T cells were present in the spleen and the lymph nodes. Until 18
weeks after reconstitution, very few B cells were present in the
spleen, whereas monocytes reached normal range. Global gene ex-
pression profiles of the two subpopulations (SDF and FDF) were
analyzed using a human transcriptome cDNA microarray. Several
molecular markers for stem cells were highly expressed in the
SDF as compared to FDF: CD133 (Prominin), MDR1 (multiple
drug resistance gene 1), clqr1 (complement component 1 receptor
1), Hoxa9, Cdx1 andHesx1 (which encode homeodomain proteins).
Our data indicated that SDF was enriched for primitive human
HSC, which were able to engraft in the thymus and lymph nodes
in the SCIDmouse model. These cells were able to give rise to pre-
cursor as well as mature T cells. Our results have provided unequiv-
ocal evidence that SDF is associated with primitive HSC function,
and is consistent with the results of differential gene expression
analysis in SDF. The significance of the cell-cell contacts in the
SCID model in maintaining stemness is currently being examined.
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TARGETING MUC1 AS A MARKER FOR MYELOID LEUKEMIA STEM CELLS
BY DC/AML FUSIONS
Rosenblatt, J.1, Wu, Z.2, Lenahan, C.1, Bissonnette, A.2, Vasir, B.2,
Miller, K.1, Joyce, R.1, Levine, J.D.1, Galinsky, I.2, Stone, R.2,
Kufe, D.2, Avigan, D.1. 1Beth Israel Deaconess Medical Center; 2Dana
Farber Cancer Institute.
The epithelial mucin antigen (MUC1) is aberrantly expressed in
many epithelial tumors and hematologic malignancies and has
served as a target for cellular immunotherapy. In this study, we ex-
aminedMUC1 as amarker formyeloid leukemia cells and their pro-
genitors. Myeloid leukemia cells were isolated from bone marrow
aspirates or peripheral blood. MUC1 was not expressed on unse-
lected leukemia cells (mean expression 3%, n 5 12). A subset of
samples underwent CD34 selection by magnetic bead separation.
In contrast to unselected cells, 38% of CD341 leukemia cells ex-
pressed MUC1 (n 5 5). The leukemia stem cell compartment was
isolated by separating CD341/CD38-/lineage- fractions by flow
cytometric sorting. Leukemia stem cells expressed MUC1 both by
immunohistochemistry and FACS analysis. Similarly, we examined
MUC1 expression on progenitor cells derived from chronic phase
CML and following blast transformation. MUC1 was seen in only
4% of CD341 cells obtained from chronic phase CML samples
(n 5 4) while uniform expression was observed in samples derived
from patients with accelerated/blast phase. These data suggest
that MUC1 serves as a marker for early leukemia progenitors and
is associated with blastic transformation. We assessed the capacity
of a dendritic cell (DC)/myeloid leukemia fusion cell vaccine to
stimulate immune responses that target MUC1 and other antigens
expressed by the stem cell compartment. DCs were generated from
adherent mononuclear cells cultured with GM-CS, IL-4 and
TNFa. DCs were fused with patient derived myeloid leukemia cells
using polyethylene glycol. Fusion cells were quantified by deter-
mining the percentage of cells that expressed unique DC and leuke-
mia antigens. Stimulation of autologous T cells with DC/AML
fusions resulted in a mean 3 fold increase in CD81 cells binding
the MUC1 tetramer (N5 4). DC/AML fusions stimulated anti-tu-
mor immune responses that targeted leukemia stem cells. Fusion
stimulated T cells demonstrated increased expression of IFNg fol-
lowing exposure to lysate generated from unselected leukemia cells(29 fold) and leukemia stem cells (28 fold). In contrast, exposure to
renal carcinoma lysate generated only a 5 fold increase in IFNg. In
summary, this data suggests that leukemic progenitors in AML and
accelerated/blast phase CML express MUC1. DC/tumor fusion
vaccines target MUC1 and the stem cell compartment, and may
be a potent immunotherapeutic strategy to eliminate the malignant
stem cell clone in AML.SUPPORTIVE CARE75
PREVENTION OF LATE CMV DISEASE AFTER HCT: A RANDOMIZED DOU-
BLE-BLIND MULTICENTER TRIAL OF VALGANCICLOVIR (VGCV) PRO-
PHYLAXIS VERSUS PCR-GUIDED GCV/VGCV PREEMPTIVE THERAPY
Boeckh, M.1, Nichols, G.1, Chemaly, R.2, Papanicolaou, G.3, Wingard, J.4,
Kirby, K.A.1, Dahlgren, C.1, Corey, L.1, Leisenring, W.1. 1Fred Hutchin-
son Cancer Research Center, Seattle, WA; 2MD Anderson Cancer Center,
Houston, TX; 3Memorial Sloan Kettering Cancer Center, New York, NY;
4University of Florida, Gainesville, FL.
Background:LateCMVdisease is an important complication af-
ter allogeneicHCT. PCR surveillance followed by preemptive ther-
apy (PET) is costly and often not feasible. VGCV prophylaxis may
prevent late CMV-related complications. Methods: Between day
80 and day 120 after HCT, CMV seropositive or D1/R- allograft
recipients with CMV infection prior to day 80 or GVHDwere ran-
domized to receive VGCV prophylaxis (900 mg/day) or placebo
(Plac) until day 270. Patients were monitored weekly for CMV
DNA by plasma PCR, blood chemistry and CBC/differential. IV
GCV (5 mg/kg twice daily) or VGCV (900 mg/kg twice daily)
was given if CMVDNA was. 1000 copies/mL. The primary end-
point was a composite of CMV disease or invasive bacterial/fungal
infection or death by day 270 and the study was designed to show
superiority of VGCV prophylaxis. Follow-up was until day 640 af-
ter HCT.Neutropenia was analyzed while receiving study drug and
by day 270. All analyses were by intent-to-treat. Results: 184 pa-
tients were randomized. All patients completed follow-up through
day 270; 84% (VGCV) and 82% (Plac) completed follow-up
through day 640 (as of 9/30/2007). There was no observed differ-
ence between the groups in the primary endpoint at day 270
(VGCV: 20%, Plac: 21%, hazard ratio [HR] 1.0, 95% CI 0.5–1.9,
P 5 0.96) and 640 (39% and 40%, HR 0.9, 95% CI 0.6–1.5, P 5
0.8). Valganciclovir prophylaxis reduced CMV PCR positivity
(11% and 36%, HR 0.3, 95% 01.-0.5, P 5 0.0002). There was
a trend towards more neutropenia on double-blind study drug (ab-
solute neutrophil count [ANC]\ 1000/mm3 43% and 29%, HR
1.7, 95%CI 0.9–2.9, P5 0.08) but no significant difference was ob-
served at day 270 (HR 1.3, 95% CI 0.8–2.1, p 5 0.21 for ANC\
1000/mm3). The number and severity of adverse events AEs (in-
cluding SAEs) was similar between the groups. There was also no
significant difference in secondary endpoints, including CMV dis-
ease at day 270 (2% in both groups, HR 0.9, 95% CI 0.1–6.5) and
640 (6% and 5%, HR 1.2, 95% CI 0.3–4.5), HSV/VZV infections
by day 640, death at any time, or relapse of the underlying disease.
Conclusion: VGCV prophylaxis was not superior in reducing the
composite endpoint of CMV disease, invasive bacterial or fungal in-
fection or death. The incidence of CMV disease was low in both
groups. VGCV reduced CMV DNAemia and the need for PET.
The rate of neutropenia and other AEs was high but not signifi-
cantly different between the groups. The study was not designed
to test for equivalency.76
AN INTERNATIONAL COMPARISON OF CURRENT STRATEGIES TO PRE-
VENT HERPESVIRUS AND FUNGAL DISEASES IN HCT RECIPIENTS
Heugel, J.1, Storek, J.2,3, Young, J.-A.3,4, Kukreja, M.3, Gress, R.3,5,
Tomblyn,M.3,4, Boeckh,M.1,3. 1Fred Hutchinson Cancer Research Center,
Seattle, WA; 2University of Calgary, AB, Canada; 3Center for Interna-
tional Bone andMarrow Transplantation Research; 4University of Minne-
sota, Minneapolis, MN; 5National Institutes of Health, Bethesda, MD.
